Denis Migliorini
YOU?
Author Swipe
View article: CTIM-27. PEMBROLIZUMAB IN COMBINATION WITH THE MULTIPEPTIDE VACCINE IMA950 ADJUVANTED WITH POLY-ICLC FOR RELAPSING GLIOBLASTOMA: A RANDOMIZED PHASE I/II TRIAL (IMA950-106)
CTIM-27. PEMBROLIZUMAB IN COMBINATION WITH THE MULTIPEPTIDE VACCINE IMA950 ADJUVANTED WITH POLY-ICLC FOR RELAPSING GLIOBLASTOMA: A RANDOMIZED PHASE I/II TRIAL (IMA950-106) Open
Immunotherapy offers a promising alternative approach for patients with glioma. In this study, we conducted a phase I/II clinical trial to evaluate the safety and tolerability of a multipeptide therapeutic vaccine (IMA950) comprising nine …
View article: Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma
Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma Open
Background Glioblastoma (GBM) is an aggressive brain tumor associated with poor outcome and limited treatment options. Chimeric antigen receptor (CAR) T cells targeting cell surface antigens were shown to induce tumor regression in patient…
View article: Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence
Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence Open
Glioblastoma is a highly aggressive brain tumour with a high risk of recurrence after surgery, even when combined with chemotherapy and radiotherapy. A major barrier to lasting treatment is the tumour’s immunosuppressive environment, which…
View article: CTSI-03 IT-IO: INTRATHECAL ADMINISTRATION OF NIVOLUMAB AND IPILIMUMAB IN COMBINATION WITH SYSTEMIC COMBINATION OF NIVOLUMAB AND IPILIMUMAB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER OR MELANOMA AND NEWLY DIAGNOSED LEPTOMENINGEAL METASTASIS, A MULTICENTRIC PHASE I STUDY
CTSI-03 IT-IO: INTRATHECAL ADMINISTRATION OF NIVOLUMAB AND IPILIMUMAB IN COMBINATION WITH SYSTEMIC COMBINATION OF NIVOLUMAB AND IPILIMUMAB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER OR MELANOMA AND NEWLY DIAGNOSED LEPTOMENINGEAL METASTASIS, A MULTICENTRIC PHASE I STUDY Open
BACKGROUND The optimal management of patients with leptomeningeal metastases (LM) from non-small cell lung cancer (NSCLC) or melanoma remains controversial. IT-IO (NCT05598853) is a prospective phase I, multicenter, open label, interventio…
View article: Glioma mimicking a cystic infectious disease: A case report of multifocal, multicentric cystic glioblastoma
Glioma mimicking a cystic infectious disease: A case report of multifocal, multicentric cystic glioblastoma Open
Background: Glioblastoma multiforme (GBM) is a highly aggressive malignant tumor known to be a great mimicker. Multicystic metastasis and cystic GBM are not rare but multicystic diffuse GBM was never reported before. Case Description: We d…
View article: Estrogens determine the efficacy of cancer immunotherapy in obese males with melanoma
Estrogens determine the efficacy of cancer immunotherapy in obese males with melanoma Open
Although obesity is a major risk factor for cancer, it may also improve the response to cancer therapy. Here we investigated the impact of obesity on the efficacy of immune checkpoint inhibitors (ICI). In male mice, obesity promoted tumor …
View article: Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure
Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure Open
Chimeric antigen receptor (CAR) T cell therapy is one of the most promising cancer treatments. However, different hurdles are limiting its application and efficacy. In this context, how aging influences CAR-T cell outcomes is largely unkno…
View article: Unveiling the Molecular Architecture of T Cells and Immune Synapses with Cryo-Expansion Microscopy
Unveiling the Molecular Architecture of T Cells and Immune Synapses with Cryo-Expansion Microscopy Open
Summary Cellular communication is critical for anti-cancer immunity, with tumor cell killing occurring at immunological synapses (IS) formed between effector immune cells and target tumor cells. While optical super-resolution microscopy (S…
View article: Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors Open
Representativeness of Study Participants
View article: Surgical and clinical impacts of mixed reality-guided glioblastoma resection versus standard neuronavigation: improving tumor surgery
Surgical and clinical impacts of mixed reality-guided glioblastoma resection versus standard neuronavigation: improving tumor surgery Open
Background Glioblastomas (GBM) are typically treated with surgery and radio-chemotherapy, with patient survival often depending on the extent of tumor resection. This study compares outcomes of GBM surgery using 5-ALA, intraoperative neuro…
View article: Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade
Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade Open
Glioblastoma (GBM) is an aggressive primary brain tumor with dismal clinical prognosis and resistance to current therapies. GBM progression is facilitated by the tumor microenvironment (TME), with an immune infiltrate dominated by tumor-as…
View article: Data from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Data from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma Open
The great success of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with B-cell malignancies has prompted its translation to solid tumors. In the case of glioblastoma (GBM), clinical trials have shown modest ef…
View article: Figure S5 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Figure S5 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma Open
Use of Jurkat triple reporter cells to assess CAR tonic signaling and specificity
View article: Figure S3 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Figure S3 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma Open
Bystander killing by 471_28z CAR-T cells depends on soluble mediators and does not affect macrophages
View article: Figure S4 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Figure S4 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma Open
Bystander killing by anti-PTPRZ1 CAR-T cells using additional tumor cell lines and scFv
View article: Figure S6 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Figure S6 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma Open
Expression of effector/memory and activation/exhaustion markers by CAR-T cells in pre- vs. post-thawing samples
View article: Figure S2 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Figure S2 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma Open
Anti-PTPRZ1 CAR-T cell effector function after incubation with the Ge1302_PTPRZ1-KI cells
View article: Figure S7 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Figure S7 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma Open
In vivo anti-tumor activity of anti-PTPRZ1 CAR-T cells
View article: Table S1 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Table S1 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma Open
Primer pairs for CAR-T cell phenotyping by qPCR
View article: Figure S1 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Figure S1 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma Open
PTPRZ1 expression at the mRNA level according to different GBM clinicopathologic features
View article: CTNI-37. INTERIM SAFETY ANALYSIS OF THE PHASE IB/II RANDOMIZED ANTI-GLUTAMATERGIC DRUG REPURPOSING TRIAL GLUGLIO IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (NCT05664464)
CTNI-37. INTERIM SAFETY ANALYSIS OF THE PHASE IB/II RANDOMIZED ANTI-GLUTAMATERGIC DRUG REPURPOSING TRIAL GLUGLIO IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (NCT05664464) Open
The advent of cancer neuroscience has significantly advanced our understanding of brain tumor biology, yet the clinical implications remain largely unexplored. Glutamate, the most abundant excitatory neurotransmitter, presents a potential …
View article: Data from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
Data from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors Open
Over two decades, most cancer vaccines failed clinical development. Key factors may be the lack of efficient priming with tumor-specific antigens and strong immunostimulatory signals. MVX-ONCO-1, a personalized cell-based cancer immunother…
View article: Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors Open
Representativeness of Study Participants
View article: Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors Open
Representativeness of Study Participants
View article: PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma Open
The great success of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with B-cell malignancies has prompted its translation to solid tumors. In the case of glioblastoma (GBM), clinical trials have shown modest ef…